IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA

被引：9

作者：

Noonan, Kimberly ^{[1
]}

Colson, Kathleen ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

SEMINARS IN ONCOLOGY NURSING | 2017年 / 33卷 / 03期

关键词：

multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects; LENALIDOMIDE PLUS DEXAMETHASONE; STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; LONG-TERM SURVIVAL; ELDERLY-PATIENTS; OPEN-LABEL; CONSENSUS STATEMENT; ANTITUMOR-ACTIVITY; ORAL MELPHALAN;

D O I：

10.1016/j.soncn.2017.05.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OBJECTIVE: To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens. IMPLICATIONS FOR NURSING PRACTICE: With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.

引用

页码：279 / 291

页数：13

共 50 条

[31] Allogeneic haematopoietic cell transplantation for relapsed or progressive multiple myeloma in the era of immunomodulatory drugs and proteasome inhibitors
Schneidawind, D.
Oehrlein, K.
Weisel, K.
Faul, C.
Kanz, L.
Bethge, W. A.
BONE MARROW TRANSPLANTATION, 2013, 48 : S208 - S208
[32] Second Generation Proteasome Inhibitors in Multiple Myeloma
Gozzetti, Alessandro
Papini, Giulia
Candi, Veronica
Brambilla, Corrado Zuanelli
Sirianni, Santina
Bocchia, Monica
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (07) : 920 - 926
[33] Oxidative stress and proteasome inhibitors in multiple myeloma
Lipchick, Brittany C.
Fink, Emily E.
Nikiforov, Mikhail A.
PHARMACOLOGICAL RESEARCH, 2016, 105 : 210 - 215
[34] Novel proteasome inhibitors as therapy in multiple myeloma
Chauhan, D.
Hideshima, T.
Mitsiades, C.
Richardson, F.
Munshi, N.
Anderson, K.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 25 - 26
[35] Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
Domenger, Antoine
Ricci, Daniela
Mayau, Veronique
Majlessi, Laleh
Marcireau, Christophe
Dadaglio, Gilles
Demangel, Caroline
FRONTIERS IN ONCOLOGY, 2023, 13
[36] The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors
Alkharabsheh, Omar
Sidiqi, M. Hasib
Aljama, Mohammed A.
Gertz, Morie A.
Frankel, Arthur E.
ACTA HAEMATOLOGICA, 2020, 143 (02) : 118 - 123
[37] Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients
Byun, Ja Min
Shin, Dong-Yeop
Hong, Junshik
Kim, Inho
Kim, Hyun Kyung
Lee, Dong Soon
Koh, Youngil
Yoon, Sung-Soo
CANCER MEDICINE, 2018, 7 (03): : 831 - 841
[38] Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma
Ferrarini, M.
Ferrero, E.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (34) : 5185 - 5195
[39] Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma
Diamond, Benjamin
Rossi, Adriana C.
Pearse, Roger N.
Jayabalan, David
Perry, Arthur
Pekle, Karen
Mark, Tomer
Niesvizky, Ruben
BLOOD, 2016, 128 (22)
[40] Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma
Salvini, Marco
Bonello, Francesca
Boccadoro, Mario
Larocca, Alessandra
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 75 - 87

← 1 2 3 4 5 →